Misc. Notes Flashcards
Increasing SID is
alkalinizing
due to:
decreasing anions
increasing cations (Na K Ca Mg)
Decreasing SID is
acidifying
due to:
increasing anions (Cl protein lactate ketoacids sulfates)
decreasing cations
approx 2/3 of anion gap is due to the charge of what
-ve charge of albumin / protein
AG equation
(Na+ + K+) - (Cl- + HCO3-)
SIG simplified equation
Na+ + K+ - Cl-
Met Acidosis
dec / -BE
dec HCO3
dec TCO2
Met Alkalosis
inc BE, HCO3, TCO2
FE of x equation
(Serum cr X Urine x) / (Urine cr / Serum x) X 100
Major crossmatch
Donor RBC, Recipient serum
Minor crossmatch
Recipient RBC, donor serum
total blood vol horse
8% BW - 40L
safe to remove how much blood
20% of blood
8% of BW
approx 8L
blood txfn equation
BW x 0.08 x [(desired - actual PCV)/donor PCV]
black leg
c. chauvei
black disease
c. novyi type B
bacillary hemoglobinuria
c. novyi type D
malignant edema
clostridium septicum
clostridia affecting feedlot cattle
c. sordeli
yellow lamb dz
c. perf type A
alpha toxin
lambs - hemolysis
calves - abomasa tympani and ulcers
cattle - hemorrhagic enteritis
enterotoxemia
c. perf type B
alpha, beta, epsilon toxin
enteritis, enterotoxemia, lamb dysentery
necrotic enteritis
c. perf type C
alpha, beta toxin
+/- enterotoxemia
any neonates affected
pulpy kidney
c. perf type D
alpha, epsilon toxin
+/- enterotoxemia
sudden death
sheep affected more than goats/cattle
*focal symmetric encephalomalacia and glycosuria due to hyperglycemia
c. perf type E
abomasal ulcers in calves
Type I error
rejected null hypothesis when it was true
-no real difference existed
-the study did find a difference
Type II error
failed to reject the null hypothesis when it was false
-a true difference existed
-the study failed to detect that difference
under-powered study
source of type II error
-sample size
-variability among subjects
-difference between group means
-a-level
when does CK peak
4-6hrs
when does AST peak
24 hrs
what level of AST would indicate rhabdo vs. travel, etx
> 4000u/l
what changes when muscle cells are injured
K, PO4, and Mg leak OUT
Na, Cl, and Ca leak IN
causes and Dx of exertional rhabdo
RER - exercise test
MH - RYR1 gene (aut dom)
PSSM1 - GYS1 gene (aut dom)
PSSM2 (mus biopsy)
MYM (mus biopsy)
causes and Dx of NON-exertional rhabdo
GBED - GBE1 (aut rec)
NMD - selenium / vitE
MMM - acute master atrophy
Hypoglycin A -
RER treatment
limit NSCs
controlled daily exercise
dantrolene prior to exercise
amylase resistant glycogen is a feature of what dz
PSSM1
amylase sensitive glycogen is a feature of what dz
PSSM2
myofibrillar myopathy (MYM)
likely heritable dz of WBs and arabs
intermittent increases in CK, exertional rhabdo
large design and alpha beta crystallin aggregates
systemic calcinosis
sudden onset epaxial/gluteal muscle atrophy, incr. AST and CK in QHs <9YO
biopsy shows dystrophic calcifications
can also affect other organs ex. lung and GIT
otobuis mogini
spinous ear tick
causes painful muscle contractions - Myotonia
remove and should recover in 36 hours
inherited myotonias
congenita, dystrophia, or HYPP
SCN4A gene
HYPP
58% of QHs
autosomal co-dominant
HYPP
-Na closer to threshold, channels don’t inactivate, K efflux / Na influx
-Triggers: GA, transport, stress, cold, diet high in K
-exercise is NOT a trigger
-CK is usually normal
-Tx: drive K intracellular w/ dextrose, bicarb, calcium; acetazolamide
most common serogroup of Pasturella Multocida in ruminant respiratory disease
A
(5 groups)
most common pathologic serogroups of Man. Hemolytica
A1, A6
(A2 normal flora in cattle, pathologic in SR’s)
most common pneumonia agent in dairy calves
pasturella
causes of fibrinous pleuritis
-mannheimia hemolytica
-also histophilus somni
Amphotericin B
binds ergosterol = cell destruction
Benzimidazole Derivatives
-azoles
inhibit ergosterol biosynthesis
Itraconazole
60% bioavailability
-histo, blasto, and aspergillus
-no adverse effects at 5mg/kg SID
Ketoconazole
poor bioavailability PO
Fluconazole
good plasma, CSF, synovial, aq humor, urine concentrations at 5mg/kg PO SID
-NOT active against fusarium or aspergillus
Vorizonacole
increased volume of distribution w/ systemic administration 4mg/kg PO SID
-choice for aspergillus, crypto, fusarium, candida, bipolaris, sedosporium
conidiobolomycosis coronatus
-granulomatus, URT, increased Eos on histo
-thin walled hyphae, septet, irregular branching
-Tx: topical or intralesional amphotericin B
cryptococcus neoformans
-saphrophytic round non staining capsule
-Tx: amphotericin B IV q24h, fluconazole PO long term, or Vori
-pneumonia, abortion,meningitis, or rhinitis
pseudollescheria boydii
-nasal mycosis
-Tx: topical miconazole
-cant diff on cytology from aspergillus or fusarium
Aspergillus spp
-broad septet hyphae, acute angle branching
-GI or lung opportunistic invasion
-Tx: amphotericin B or itraconazole or Vori if there is rhinitis / sinusitis + topicals
Blastomycosis
-suceptible to amphotericin B, itraconazole, and fluconazole
Histoplasma capsulatum
-suceptible to amphotericin B, intaconazole, or fluconazole
coccioides immites
-inhaled
-causes lung granulomas
-Tx: itraconazole or fluconazole
candida albicans
-fluconazole is first choice
-c. krusei –> vori or amph. B
pneumocystis cannii
-lacks ergosterol
-exists as ameboid yeast
common in SCID foals
-Dx: BAL/TW cytology, can’t culture
-Tx: TMS
one of the following general conditions must be met before you can legally prescribe an approved human or animal drug for an extra-label use:
–There is no animal drug approved for the intended use; or
–There is an animal drug approved for the intended use, but the approved drug does not contain the active ingredient you need to use; or
–There is an animal drug approved for the intended use, but the approved drug is not in the required dosage form (for example, you need a liquid dosage form, but the approved drug is only available as a tablet dosage form); or
–There is an animal drug approved for the intended use, but the approved drug is not in the required concentration (for example, you need 5 mg, but the approved drug is only available at 50 mg); or
–You have found, in the context of a valid veterinarian-client-patient relationship, that the approved drug is clinically ineffective when used as labeled.
For production animals, FDA’s requirements for extra-label drug use
*prohibit or allow?
you from prescribing an approved human drug if there’s a drug approved for food-producing animals that you can prescribe instead.
PROHIBIT
For example, if a drug approved for chickens is available, you must first use that drug to treat a sick cow before reaching for a drug approved for people.
Drugs Prohibited from Extra-Label Uses in all food-producing animals, including horses intended for human food:
Chloramphenicol
Clenbuterol
Diethylstilbestrol (DES)
Dimetridazole
Ipronidazole and other nitroimidazoles
Furazolidone and nitrofurazone
Sulfonamide drugs in lactating dairy cattle, except for the approved use of sulfadimethoxine, sulfabromomethazine, and sulfaethoxypyridazine
Fluoroquinolones
Glycopeptides
Phenylbutazone in female dairy cattle 20 months of age or older
Cephalosporins (not including cephapirin) in cattle, swine, chickens, or turkeys:
-For disease prevention purposes;
-At unapproved doses, frequencies, durations, or routes of administration; or
-If the drug is not approved for that species and production class.
AA critical in maintaining GI mucosal integrity and immune function
glutamine
AA precursor of synthesis of nitric oxide and upregulates immune function
arginine